Review
Nature Reviews Cancer 3, 267-275 (April 2003) | doi:10.1038/nrc1043
Subject Category: Early detection
Focus on: Early detection
Early detection: Proteomic applications for the early detection of cancer
Julia D. Wulfkuhle1, Lance A. Liotta1 & Emanuel F. Petricoin2 About the authors
Abstract
The ability of physicians to effectively treat and cure cancer is directly dependent on their ability to detect cancers at their earliest stages. Proteomic analyses of early-stage cancers have provided new insights into the changes that occur in the early phases of tumorigenesis and represent a new resource of candidate biomarkers for early-stage disease. Studies that profile proteomic patterns in body fluids also present new opportunities for the development of novel, highly sensitive diagnostic tools for the early detection of cancer.
- View At a Glance
Author affiliations
- NCI/FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.
- NCI/FDA Clinical Proteomics Program, Office of the Director, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
Correspondence to: Emanuel F. Petricoin2 Email: petricoin@cber.fda.gov
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
